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Objective: Cell-based tissue engineering strategies are currently in clinical use and continue to be
developed at a rapid pace for the repair of cartilage defects. Regardless of the repair methodology,
chondrocytes within newly regenerated cartilage remain susceptible to the abnormal inﬂammatory and
mechanical environments that underlie osteoarthritic disease, likely compromising the implant’s inte-
gration, function, and longevity. The present study investigates the use of parathyroid hormone-related
peptide (PTHrP) overexpression for chondroprotection.
Design: Bovine articular chondrocytes were transfected with human PTHrP (hPTHrP) constructs (1-141 or
1-173) and subjected to injurious cyclic tensile strain (CTS; 0.5 Hz and 16% elongation) for 48 h. mRNA
expression of matrix remodeling, inﬂammatory signaling, hypertrophic, and apoptotic genes were
examined with real-time reverse transcription polymerase chain reaction. Nitric oxide (NO) and pros-
taglandin E2 (PGE2) production were measured using the Griess assay and enzyme immunoassay (EIA),
respectively.
Results: CTS-induced an arthritic phenotype in articular chondrocytes as indicated by increased gene
expression of collagenases and aggrecanases and increased production of NO and PGE2. Additionally, CTS
increased collagen type X (Col10a1) mRNA expression, whereas overexpression of either hPTHrP isoform
inhibited CTS-induced Col10a1 gene expression. However, hPTHrP 1-141 augmented CTS-induced NO
and PGE2 production, and neither hPTHrP isoform had any signiﬁcant effect on apoptotic genes.
Conclusions: Our results suggest that chondrocytes overexpressing PTHrP resist mechanical strain-
induced hypertrophic-like changes. Therapeutic PTHrP gene transfer may be considered for chon-
droprotection applications in newly regenerated cartilage.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
A number of surgical and cell-based regenerative strategies have
been evaluated for the repair of cartilage defects. Current surgical
techniques include mechanical penetration of the subchondral
bone (i.e., abrasion arthroplasty, Pridie drilling, or microfracture)
and autologous transplantation of periosteum, perichondrium, or
osteochondral grafts1. Autologous chondrocyte implantation (ACI)
is in current clinical application to mitigate progression to disease2,: Rocky S. Tuan, Center for
thopaedic Surgery, University
ive, Room 221, Pittsburgh, PA
s Research Society International. Pand tissue engineering approaches that deliver a matrix seeded
with chondrogenic cells and chondrogenic factors have also been
evaluated experimentally. Regardless of the methodology, newly
implanted chondrocytes within the defect remain susceptible to
the abnormal inﬂammatory and mechanical environments that
underlie osteoarthritic disease3,4. Subsequent arthritis-associated
changes and aberrant functioning of these chondrocytes are likely
to eventually compromise the integration, function, and longevity
of regenerated cartilage5. Thus, chondroprotection of regenerated
cartilage from the underlying disease would result in a more
effective and durable therapy.
Resident chondrocytes provide the essential function of main-
taining cartilage matrix homeostasis. This activity is impaired after
traumatic mechanical loads damage articular cartilage during
post-traumatic arthritis and osteoarthritis (OA)6,7. Derangement of
the extracellular matrix (ECM) signiﬁcantly alters chondrocyteublished by Elsevier Ltd. All rights reserved.
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degradation process by up-regulation of matrix-degrading prote-
ases, such as matrix metalloproteinases (MMPs) and a disintegrin
and MMP with thrombospondin motifs (ADAMTSs), as well as
inﬂammatory intermediaries, including nitric oxide (NO) and
prostaglandins (PGs)8. These increased proteolytic activities are not
sufﬁciently counterbalanced by an increase in chondrocyte anabolic
activities, resulting in matrix erosion. Another interesting aspect in
the arthritis disease process is the recapitulation of molecular
mechanisms that occur during fetal skeletogenesis. In addition to
changes in anabolic and catabolic events, there are changes in
cellular phenotype similar to those found in endochondral ossiﬁ-
cation, including hypertrophic differentiation, matrix calciﬁcation,
and apoptosis9. Previous studies have found increased expression of
hypertrophic markers in OA cartilage, including type X collagen,
Indian hedgehog (Ihh), MMP-13, and alkaline phosphatase
(ALP)9e12. Expression of these markers, which are typically low to
absent in normal healthy cartilage, suggests that the progression of
the degenerative cascade may involve the loss of inhibitory control
over terminal differentiation genes in osteoarthritic chondrocytes.
Parathyroid hormone-related protein (PTHrP) maintains the
function of proliferating chondrocytes and inhibits chondrocyte
differentiation toward hypertrophy in the growth plate13. The anti-
hypertrophy activity has been shown to result from binding of the
N-terminus of PTHrP to its cell surface receptor (PTH1R), activating
sex determining region Y box 9 (Sox9)14,15. PTHrP also stimulates
proliferation of endochondral chondrocytes and inhibits apoptosis,
partly via induction of B-cell lymphoma 2 (Bcl-2)16,17. Therefore,
PTHrP may be a therapeutic option for the protection of articular
chondrocytes. Additionally, previous studies have used gene transfer
methods to provide sustained transgene expression for the purposes
of cartilage repair and chondroprotection18. The efﬁcacy of sustained
PTHrP transgene expression by articular chondrocytes in preserving
phenotypic homeostasis remains unknown.
The present study explored the use of human PTHrP (hPTHrP)
overexpression by articular chondrocytes to suppress arthritic-like
changes induced by mechanical trauma. Two different PTHrP iso-
forms, 1-141 and 1-173, were tested. A cyclic tensile strain (CTS)
model was used to promote arthritic changes in articular chon-
drocytes in vitro.
Materials and methods
Chondrocyte isolation and culture
Chondrocytes were isolated from the knees of adult steers (2e3
years old) using previously described methods19. Brieﬂy, cartilage
slices were diced ﬁnely and digested in a stirring ﬂask for 8e10 h
with 0.2% collagenase type II (Sigma) in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) (Invitrogen) supplemented with antibiotics at
37C under 5% CO2. After ﬁltration through a 40 mmnylonmesh cell
strainer, the cells were re-suspended at a density of 1.5105 cells/
cm2 in DMEM supplemented with 10% fetal bovine serum (FBS) and
antibiotics for 2 days, and frozen for later use in liquid nitrogen.
Transfection procedure and plasmid DNA
Cells were thawed in DMEM with 10% FBS for 2 days before
transfection. First, chondrocytes were treated with 40 U/ml bovine
testicular hyaluronidase (Sigma) for 3 h. Next, medium was
replaced with a transfection solution containing Opti-MEM-
IþGlutaMAX-I (Invitrogen), 4 U/ml hyaluronidase, FuGENE 6
(Roche), and plasmid DNA. Optimal transfection of bovine articular
chondrocytes used a lipid/DNA ratio of 3:120. After 6 h, the trans-
fection solution was replaced with DMEM with 10% FBS.Transfection efﬁciency using this protocol was observed to be
approximately 35% with GFP control plasmids.
hPTHrP 1-141 and 1-173 plasmids were generous gifts from
Dr. Leonard J. Deftos, University of California, San Diego21. Both
constructs were inserted downstream of a cytomegalovirus (CMV)
promoter/enhancer in the pCI-neo expression plasmid vector
(Promega). Control cells were simultaneously transfected with the
blank pCI-neo vector. All plasmids were ampliﬁed and puriﬁed by
MTR Scientiﬁc (Ijamsville, MD).
Application of CTS
Chondrocytes were trypsinized and cultured onto ﬁbronectin-
coated Bioﬂex plates (Flexcell) at a density of 40,000 cells/cm2 in
DMEM with 1% FBS for 1 day. Bioﬂex plates were coated with 5 mg/
ml bovine plasma ﬁbronectin (Sigma) in 0.1 M bicarbonate solution
for 3 h at 4C, then replaced with DMEM with 10% FBS and incu-
bated overnight to remove non-adherent ﬁbronectin. Wells were
rinsed with Hanks Balanced Salt Solution (HBSS) immediately
before seeding. Cells were subjected to equibiaxial tensile strain
using a custom manufactured vacuum-operated loading device. A
pulsed waveform 16% CTS and 0.5 Hz frequency was applied.
Seeding of cells onto the Bioﬂex plates and application of CTS were
completed at 37C under 5% CO2 and 5% O2. A 5.0% ambient oxygen
tension environment was maintained with a dual gas incubator
(Forma II 3130, Thermo Scientiﬁc) and used to simulate normal
physiologic conditions and reduce the production of reactive
oxygen species relative to standard normoxic culture conditions.
Cell viability at the end of experimentation was observed using
LIVE/DEAD staining (Invitrogen) to detect live (green ﬂuorescence)
and dead (red ﬂuorescence) cells.
RNA extraction and quantitative real-time PCR
Chondrocytes were homogenized in TRIzol reagent (Invitrogen)
at 0, 12, 24, and 48 h of CTS to extract total cellular RNA, which was
further treated with Turbo DNase (Ambion) for 25 min at 37C to
remove genomic DNA. RNA concentration and purity were esti-
mated spectrophotometrically on the basis of absorbance values at
260 nm and 280 nm. Reverse transcription of equal quantities of
RNA (1 mg) from each sample was performed using SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen).
Real-time PCR was performed using the Stratagene Mx3000P
instrument and Power SYBR Green PCR Master Mix (Applied Bio-
systems). Select PCR primers were designed using Primer3 v0.4.0.
(Whitehead Institute for Biomedical Research) on the basis of
bovine mRNA sequences (primer sequences available on request).
The ampliﬁcation program was as follows: denaturation, 95C,
10 min; 40 ampliﬁcation cycles, 95C, 30 s; and annealing, 60C,
1 min. After ampliﬁcation, melt analysis was performed by heating
the reaction mixture from 60C to 95C at a rate of 0.2C/s. Relative
fold changes relative to the time zero control samples (24 h post
seeding but pre-CTS) were calculated using the comparative
threshold cycle (CT) method (DDCT) with glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) as the control gene. Four house-
keeping genes were tested (GAPDH, HPRT, b2 M, RPL13a), and
GAPDH was found to be the most stable with a max fold change of
0.26 from baseline after 48 h. Neither CTS nor PTHrP signiﬁcantly
affected expression of the housekeeping genes.
Enzyme immunoassay (EIA) and biochemical analysis
Culture medium aliquots were stored at 80C prior to
biochemical analyses. Relative concentrations of NO were
measured in the culture media using the Griess assay (Promega).
Fig. 1. Cell viability at the end of experimentation was observed using LIVE/DEAD staining to detect live (green ﬂuorescence) and dead (red ﬂuorescence) cells. The majority of
chondrocytes (>90%) remained viable after 48 h of (A) No CTS and (B) CTS.
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that uses sulfanilamide and N-1-napthylethylenediamine dihy-
drochloride (NED) under acidic (phosphoric acid) conditions. This
system measures nitrite, which is one of two primary, stable and
nonvolatile breakdown products of NO. PGE2 production was
measured in the culture media using a high-sensitivity EIA kit
(Assay Designs). Total PTHrP production was measured in the
culture media using an EIA kit (Bachem), which is designed to
measure the 1e34 peptide sequence and detects both human and
bovine PTHrP, but does not cross-react with PTH. All biochemical
assays were normalized to number of viable cells, which was
determined quantitatively using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega).Table I
Gene expression changes in articular chondrocytes subjected to 48 h of CTS
Gene CTS* No CTS* P-valuey
Col2a1 0.11 0.25 0.050
Aggrecan 0.15 0.17 0.148
MMP-1 1.28 0.34 0.010
MMP-3 2.49 0.81 0.080
MMP-9 3.29 2.39 0.010
MMP-13 1.37 2.36 0.049Statistical analysis
Each experiment was performed three times with different
chondrocyte sources. Proportional fold changes are presented using
the means [95%conﬁdence interval (CI)] from a single replicate
experiment, and statistical analyses were carried out by GraphPad
Prism ﬁve using three replicate experiments. Two-tailed t-tests
were used to compare gene expression differences between CTS
and no CTS conditions. Two-way analysis of variance (ANOVA) with
post hoc Bonferroni-corrected t-tests were used to compare
differences between the three different PTHrP treatment
conditions (control, 1-141, 1-173) for both CTS and no CTS
conditions. Statistical signiﬁcance was based on P< 0.05.ADAMTS-4 9.92 0.72 0.087
ADAMTS-5 0.34 0.81 0.074
TIMP-1 0.23 0.20 0.067
TIMP-2 0.36 0.10 0.073
TIMP-3 2.21 0.31 0.005
Col10a1 3.93 0.93 0.007
ALP 0.19 0.27 0.159
Runx2 0.57 0.14 0.047
bPTHrP 3.72 0.56 0.000
PTHR1 1.04 0.13 0.016
CTGF 0.62 0.01 0.010
Sox9 0.51 0.18 0.044
iNOS 4.66 0.80 0.010
COX-2 0.85 0.21 0.006
Bcl-2 1.17 0.04 0.006
Bcl-xL 1.08 0.07 0.018
Bax 0.24 0.03 0.067
ADAMTS e a disintegrin and metalloproteinase with thrombospondin motifs;
Col10a1 e collagen type Xa1; PTHR1 e PTHrP receptor; CTGF e connective tissue
growth factor.
* Proportional fold changes of mRNA levels over 48 h, compared to time zero, of
CTS and no CTS conditions presented as mean of N¼ 3.
y P-Values were calculated from two-tailed t-tests.Results
Effects of 16% CTS on articular chondrocytes
When observed under light microscopy, unstrained cells
continued to adhere and spread in monolayer during the experi-
mental period. CTS caused most adherent cells to retain their round
shape, while others took on a more stellate-shaped appearance.
The majority of chondrocytes (>90%), regardless of their shape,
remained viable after undergoing 48 h of CTS (Fig. 1). Furthermore,
the number of viable cells between CTS and No CTS conditions, as
measured by proliferation assays, was similar at all time points. The
effects of CTS were ascertained by measuring the mRNA levels of
multiple genes (Table I). All MMP, ADAMTS, and tissue inhibitors of
metalloproteinases (TIMP) gene levels were up-regulated by CTS.
MMP-3 (stromelysin 1) and MMP-13 (collagenase 3) mRNA levels
in strained chondrocytes were increased 3.31 and 3.73 times,
respectively, over levels in unstrained chondrocytes after 48 h[Fig. 2(A)]. ADAMTS-4 (aggrecanase 1) and ADAMTS-5 (aggrecanase
2) mRNA levels were increased in strained chondrocytes 10.63 and
1.14 times, respectively, over levels in unstrained cells after 48 h
[Fig. 2(B)]. In comparison, mRNA levels of these genes in unstrained
cells did not change by more than 0.81-fold from time zero levels;
changes in MMP-9 and MMP-13 mRNA levels were the only
exceptions (2.39 and 2.36, respectively). CTS decreased gene
expression of collagen type IIa1 (Col2a1) by 0.37-fold from no CTS
controls but did not alter expression of aggrecan over 48 h [Fig. 2
(C)]. The hypertrophy-associated genes, Col10a1 and runt-related
transcription factor 2 (Runx2), were signiﬁcantly up-regulated
3.00-fold and 0.43-fold, respectively, by CTS over no CTS conditions
after 48 h [Fig. 2(D)]. Col10a1 gene expression was immediately
increased with application of CTS, with signiﬁcant increases at all
measured time points. In comparison, Col10a1 mRNA levels
increased by an average of only 0.93-fold over the 48-h experi-
mental period under no CTS conditions. Gene expression of
Fig. 2. Effects of 16% CTS on normal bovine articular chondrocytes. CTS increased gene expression of (A) MMPs, (B) ADAMTSs, (D) hypertrophic genes, and (F) iNOS and COX-2 and
decreased gene expression of (C) Col2a1. CTS increased secretion of (D) NO and PGE2, which correlates with (E). Error bars represent 95% CIs (N¼ 3). Solid lines¼ CTS; Dotted
lines¼No CTS. *¼ P< 0.05 and **¼ P< 0.01 vs control. Speciﬁcally, MMP-13 48 h P¼ 0.0493, 24 h P¼ 0.0465; Col2a1 48 h P¼ 0.0498; Col10al P¼ 0.0072, 24 h P¼ 0.0124, 12 h
P¼ 0.0122; Runx2 48 h P¼ 0.0471; iNOS 48 h P¼ 0.0097, 24 h P¼ 0.0139; COX-2 48 h P¼ 0.0059, 24 h P¼ 0.0130, 12 h P¼ 0.0075; NO 48 h P¼ 0.0397, 24 h P¼ 0.0301; PGE2 48 h
P¼ 0.0147, 24 h P¼ 0.0066.
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cyclooxygenase-2 (COX-2) were up-regulated 5.46-fold and 1.06-
fold, respectively, over no CTS controls after 48 h of CTS. Secretion
of their respective mediators, NO and PGE2, were signiﬁcantly
increased 5.17 and 4.50 times over controls after 48 h of CTS [Figs. 2
(E and F)]. NO and PGE2 levels in unstrained chondrocytes
remained low and changed minimally over the course of the
experimental period.Total PTHrP secretion after transfection of articular chondrocytes
Chondrocytes transfectedwith either hPTHrP construct secreted
more total PTHrP under both CTS and no CTS conditions [Fig. 3(A),
CTS data shown]. Under CTS conditions, chondrocytes expressing
1-141 and 1-173 secreted an average 1.59 and 1.39 times more total
PTHrP than control cells, respectively, at 48 h; under no CTS
conditions, chondrocytes expressing 1-141 and 1-173 secreted an
average of 1.27 and 1.12 times more total PTHrP than control cells,
respectively, at 48 h. Additionally, chondrocytes expressing hPTHrP
1-141 secreted more total PTHrP than those expressing hPTHrP
1-173 at all measured times, although the differences were not
signiﬁcant.Several trends in PTHrP secretion by control cells were
observed. When comparing CTS and no CTS conditions, CTS
signiﬁcantly increased PTHrP secretion by 1.31 times over that in no
CTS cells at 24 h [Fig. 3(A)]. Additionally, while total PTHrP secre-
tion generally trended down during experimental period with CTS,
endogenous PTHrP gene expression was signiﬁcantly up-regulated
by CTS as measured by real-time PCR [Fig. 3(B)]. After 48 h of CTS,
bovine parathyroid hormone-related peptide (bPTHrP) gene
expression increased 4.28-fold over no CTS controls. However,
chondrocytes expressing hPTHrP 1-141 and 1-173 demonstrated
a 1.68- and 1.21-fold feedback inhibition, respectively, of endoge-
nous bPTHrP mRNA levels.hPTHrP overexpression inhibits CTS-induced Col10a1 gene
expression
PTHrP overexpression suppressed both basal and CTS-induced
Col10a1 gene expression. hPTHrP 1-141 and 1-173 expression
suppressed CTS-induced Col10a1 mRNA levels during all measured
time points [Fig. 4(A)]. Increases in Col10a1 gene levels by CTS were
inhibited signiﬁcantly by 2.39- and 1.86-fold, respectively, at 48 h
and by 0.85- and 0.92-fold, respectively, at 24 h. In comparison,
Fig. 3. Total PTHrP secretion by articular chondrocytes transfected with hPTHrP expression constructs. (A) Chondrocytes expressing hPTHrP constructs secrete more total PTHrP
(bovine and human) under CTS and No CTS conditions (only CTS data shown). Error bars represent 95% CIs (N¼ 3). *¼ P< 0.05 and **¼ P< 0.01 vs control. # Denotes P¼ 0.0102
vs No CTS control. (B) Endogenous PTHrP (bPTHrP) gene expression, as measured by RT-PCR using a primer speciﬁc for the bovine gene, was up-regulated by CTS. Chondrocytes
expressing hPTHrP 1-141 and 1-173 demonstrated feedback inhibition of endogenous bPTHrP mRNA levels. Error bars represent 95% CIs (N¼ 3). **¼ P< 0.01 control vs hPTHrP
1-141 and 1-173.
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signiﬁcantly by 0.84- and 0.62-fold, respectively, at 48 h in no CTS
cells [Fig. 4(B)]. hPTHrP did not signiﬁcantly affect expression of
matrix remodeling genes.Effects of hPTHrP overexpression on CTS-induced iNOS and COX-2
gene expression and NO and PGE2 production
Expression of hPTHrP 1-141 augmented CTS-induced iNOS
gene expression at 24 h by 1.99-fold, although the differences
were not signiﬁcant [Fig. 5(A)]. However, hPTHrP 1-141
augmented CTS-induced NO production signiﬁcantly at all
measured time points, with an average 1.81 times increased
production vs control at 48 h [Fig. 5(B)]. In addition, hPTHrP 1-141
augmented both COX-2 gene levels and PGE2 production by 1.20-
and 1.78-fold over control levels at 48 h [Fig. 5(C and D)]. Chon-
drocytes overexpressing hPTHrP 1-173 exhibited similar iNOS and
COX-2 mRNA levels as control, with a maximum 0.61-fold change
during the experimental period. NO and PGE2 production between
1-173 and control groups were almost identical as well, with
a maximum 0.10-fold change during the experimental period.
Under no CTS conditions, neither hPTHrP isoform affected iNOS
and COX-2 mRNA levels or NO and PGE2 production, all of which
remained low and showed minimal change during the experi-
mental period.Fig. 4. Inhibition of Col10a1 gene expression in articular chondrocytes by PTHrP overexpr
Col10a1 gene expression and (B) basal Col10a1 gene expression. hPTHrP overexpression had
95% CIs (N¼ 3). *¼ P< 0.05 and **¼ P< 0.01 vs hPTHrP 1-141 and 1-173.Effect of hPTHrP overexpression on CTS-induced apoptotic gene
expression
CTS increased Bcl-2 and Bcl-2-associated X protein (Bax) gene
expression by 1.21- and 0.27-fold, respectively, over no CTS controls
after 48 h. Neither hPTHrP isoform had any signiﬁcant effect on
Bcl-2 or BaxmRNA levels [Fig. 6(A and B), CTS data shown]. The Bcl-
2/Bax mRNA ratio was calculated, which also did not change
signiﬁcantly upon hPTHrP overexpression when compared to
control [Fig. 6(C)]. Finally, basal Bcl-2 and Bax expression levels in
unstrained chondrocytes remained low and changed minimally
during the experimental period and were not altered by hPTHrP
overexpression (data not shown).
Discussion
Cell-based tissue engineering strategies are currently in clinical
use and continue to be developed at a rapid pace for the repair of
cartilage defects. Regardless of the repair methodology, newly
created joint cartilage will still be susceptible to the abnormal
inﬂammatory and mechanical environments that underlie osteoar-
thritic disease, potentially compromising its integration, function,
and longevity. Chondroprotection measures must therefore be
designed for the chondrocytes of regenerated cartilage, which are in
close proximity to matrix proteases, bioactive ECM fragments, and
inﬂammatory mediators responsible for degenerative OA. Previousession. Expression of exogenous hPTHrP in chondrocytes suppressed (A) CTS-induced
no signiﬁcant effect on matrix remodeling genes (data not shown). Error bars represent
Fig. 5. Effects of hPTHrP overexpression on CTS-induced iNOS and COX-2 gene expression and NO and PGE2 production in articular chondrocytes. Overexpression of hPTHrP 1-141
augmented gene expression of inducible enzyme isoforms, (A) iNOS and (C) COX-2, and production of their respective inﬂammatory mediators, (B) NO and (D) PGE2. Chondrocytes
overexpressing hPTHrP 1-173 did not show signiﬁcant changes in iNOS and COX-2 gene expression or production of NO and PGE2 when compared to control. Error bars represent
95% CIs (N¼ 3). *¼ P< 0.05 and **¼ P< 0.01 vs control.
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chondrocytes during the progression of OA are similar to those in the
cartilage growth plate during developmental endochondral ossiﬁ-
cation. Speciﬁcally, articular chondrocytes reinitiate a sequence of
phenotypic changes that begin with hypertrophy and progress
towardmineralization and apoptosis9,10,22,23. Increased productionof
catabolic proteases, includingMMP-1,MMP-3,MMP-9, andMMP-13,
has been observed both in the growth plate and OA cartilage,
resulting in matrix degradation in both processes12,24e28.
Because the progression of the degenerative cascade is thought
to involve the loss of inhibitory control over terminal differentia-
tion genes, we hypothesized that an anti-hypertrophic therapymay
protect healthy chondrocytes from arthritic disease. PTHrP is an
important signaling factor in the regulation of endochondral ossi-
ﬁcation in the epiphyseal growth plate of long bones. Within cells,
PTHrP is processed by members of the family of prohormone
convertases to at least three fragments with different biologic
functions29,30. Several direct effects of these fragments make it anFig. 6. Effects of hPTHrP overexpression on CTS-induced apoptotic gene expression in artic
not show any signiﬁcant change in CTS-induced (A) Bcl-2 and (B) Bax gene expression level
represent 95% CIs (N¼ 3).attractive option for chondroprotection therapy. Suppression of
hypertrophy and terminal differentiation is mediated through
parathyroid hormone receptor 1 (PTHR1). Activation of PTHR1
leads to subsequent activation of the PKA signaling pathway,
increasing chondrocyte proliferation by decreasing p57 and Runx2
levels and increasing Sox9 phosphorylation31. Because the
N-terminal regions of PTHrP and PTH are similar and share the
same receptor (PTHR1), previous reports have shown the ability of
these peptides to suppress hypertrophic changes and terminal
differentiation of articular chondrocytes induced by T3 and 5-aza-
cytidine32,33. Additionally, PTHrP has a well-documented anti-
apoptotic effect through its translocation to the nucleus via
a mid-region bipartite nuclear targeting sequence (NTS)17,34e36.
Thus, PTHrP plays an important role inmaintaining the survival and
chondrogenesis of proliferating chondrocytes and suppressing
terminal differentiation in the growth plate.
In the present study, the effects of PTHrP in suppressing early
arthritic-like changes were ascertained in a mechanical CTS model.ular chondrocytes. Chondrocytes overexpressing either exogenous hPTHrP isoform did
s. (C) hPTHrP overexpression also did not signiﬁcantly affect Bcl-2/Bax ratio. Error bars
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sustained delivery of PTHrP will eventually be needed to inhibit the
effects of a chronic disease like OA to achieve optimal therapeutic
results. Such a mechanism of sustained PTHrP delivery was tested
by non-viral gene transfer of hPTHrP cDNA into the articular
chondrocytes themselves. This study contributes several novel
approaches and results. First, high magnitude CTS model induced
an arthritic phenotype with a similar pattern of changes as OA
chondrocytes, including increased gene expression of the collage-
nases and aggrecanases, as well as increased production of NO and
PGE2. Additionally, high magnitude CTS was discovered to increase
gene expression of Col10a1, a marker of chondrocyte hypertrophy,
and this phenomenon may be mediated by Runx2 due to their
concurrent increase. Endogenous bPTHrP gene expression
increased with CTS, consistent with increased PTHrP secretion seen
in human osteoarthritic cartilage38,39 and thought to be a self-
repair response to damaged cartilage40. Interestingly, gene
expression of PTH1R, a marker of pre-hypertrophy, decreased
initially for the ﬁrst 12 h with CTS but steadily increased for the
next 36 h (data not shown). This bimodal regulation may arise from
CTS overriding the autocrine feedback down-regulation of receptor
expression in cells producing PTHrP. However, cellular changes that
occur during recovery from trypsinization may also modulate this
response. Gene expression of ALP, a recognized marker for terminal
differentiation, did not change signiﬁcantly with 48 h of CTS. It may
be possible that only early hypertrophic genes were up-regulated
within the ﬁrst 48 h of CTS, while late hypertrophic genes would
have been up-regulated with a longer duration of CTS. Second,
sustained PTHrP delivery to chondrocytes was achieved by means
of FuGENE 6-mediated transfection of hPTHrP constructs. As
expected, chondrocytes expressing exogenous hPTHrP showed
higher secreted levels of total PTHrP (bovine and human) than
controls. Chondrocytes expressing isoform 1-141 generally secreted
more total PTHrP than those expressing isoform 1-173, which is
consistent with previous data showing that serial truncation of the
C-terminal end increases the amount of secreted PTHrP21.
Third, overexpression of both hPTHrP isoforms inhibited CTS-
induced and basal Col10a1 expression in articular chondrocytes.
Although CTS signiﬁcantly increased Runx2 mRNA levels, this
change was so slight that whether inhibition of Col10a1 expression
by hPTHrP was via Runx2 could not be ascertained. hPTHrP had no
signiﬁcant inhibitory effect on CTS-induced MMP-13 gene expres-
sion. MMP-13 is expressed by hypertrophic chondrocytes to
degrade the cartilage matrix, to facilitate vascular invasion and
matrixmineralization by osteoblasts. BecauseMMP-13 is expressed
in only the most terminally differentiated hypertrophic chon-
drocytes41, the immediate MMP-13 up-regulation observed in this
CTS model is most likely attributed to mechanotransduction rather
than phenotype modulation. hPTHrP overexpression was not
able to immediately inhibit the catabolic changes along with the
hypertrophic-like changes, suggesting that the two pathways are
regulated separately.
Lastly, CTS increased NO and PGE2 production, which both act as
strong catabolic signals in cartilage by altering chondrocyte func-
tion and enhancing chondrocyte apoptotic potential42. hPTHrP
isoform 1-141 potentiated the production of these mediators with
CTS by upregulating transcriptional levels of iNOS and COX-2.
Because these effects were not observed with isoform 1-171, the
underlying mechanism may be speciﬁc to the amount of secreted
PTHrP or to the 140e141 region that differs between the two iso-
forms. Although PTHrP is known to stimulate NO release from
endothelial cells for local regulation of vascular tone43, a possible
mechanism for PTHrP-mediated NO release in chondrocytes has
not been elucidated. Additionally, studies have found that PGE2
increases PTHrP production in chondrocytes44,45, but the reversehas not been reported. Increased production of pro-inﬂammatory
intermediaries is expected to promote apoptosis through regula-
tion of Bcl-2 and Bax gene expression in chondrocytes. Bax forms
heterodimers with Bcl-2, and when overexpressed, counters the
anti-apoptotic effect of Bcl-2, causing accelerated cell death.
Therefore, it is the ratio of Bcl-2 to Bax that determines the
apoptotic fate of a cell. Our results show that Bcl-2 and Bax gene up-
regulation by CTS follows a similar temporal pattern as hypertro-
phic chondrocytes in the growth plate16,46. Anti-apoptotic Bcl-2
gene expression was immediately increased, possibly in a rescue
attempt for survival, while pro-apoptotic Bax gene expression was
not increased until 12e24 h of CTS, when the ratio of the expression
level of Bcl-2 and Bax gradually shifts in favor of Bax. Intracellular
hPTHrP expression was expected to effect a pro-survival advantage
to chondrocytes due to translocation of the NTS to the nucleus, as
shown in previous work in the literature17,34e36. However, hPTHrP
overexpression had no signiﬁcant effect on Bcl-2 and Bax gene
expression. This result may be attributed to the short testing period.
The intact viability of themajority of cells after 48 h of CTS indicates
that the only initial stages of the apoptotic cascade were activated.
Longer follow-up times may be needed to appreciate any apoptosis
and cell death cause by CTS and thus, any anti-apoptotic effects of
hPTHrP overexpression. Interestingly, B-cell lymphoma e extra
large (Bcl-xL) gene expression was up-regulated with CTS and
augmented by expression of hPTHrP 1-141 at 48 h (data not
shown).
Several studies have reported the use of inﬂammation-respon-
sive promoters to regulate OA gene therapy47e49. Regulation of
hPTHrP expression may be necessary to selectively activate tar-
geted pathways because high concentrations of PTHrP can facilitate
activation of other heterotrimeric G proteins, including the Gq
family. The effect of Gq activation is opposite from that of Gs acti-
vation in that it mildly accelerates chondrocyte differentiation50.
The purpose of these opposing actions may be to regulate the
proliferation of chondrocytes based on their location, thus creating
a functional gradient of PTHrP across the growth plate31. PTHrP
overexpression may expose chondrocytes to concentrations that
are too high, simultaneously activating Gs and Gq pathways.
Therefore, we are currently testing the use of an inﬂammation-
responsive, self-limiting promoter consisting of NF-kB repeat
sequences to optimize PTHrP therapy.
This study demonstrates that PTHrP overexpression inhibits
CTS-induced hypertrophic-like changes of articular chondrocytes.
Several gene therapy approaches are currently being investigated
for the repair of cartilage defects and the inhibition of OA
progression. However, most of these approaches (i.e., MMP inhib-
itors) target only one of several players in the disease pathogenesis,
and none have attempted to target the early hypertrophic-like
changes seen in OA. Ultimately, a combination of these approaches
may be needed for effective chondroprotection of regenerated
cartilage. Because CTS only initiated early stage arthritic-like
changes, the long-term protective effects of PTHrP may be even
greater than indicated in this study. Future work will examine
longer-term treatment regimens to better assess the effects of
PTHrP overexpression on overall matrix metabolism and chon-
drocyte survival under mechanical loading conditions.Author contributions
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